Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366635 | 0.86 | CASR (0.46) | CASRMAPTMEN1KMT2ATDP1 | |
| SCHEMBL4366631 | 0.86 | CASR (0.46) | CASRMAPTMEN1KMT2ATDP1 | |
| SCHEMBL4374351 | 0.79 | CASR (0.52) | CASRMAPTMEN1KMT2AADRB2 | |
| SCHEMBL4364972 | 0.78 | PTPN1 (0.38) | CASRMAPTMEN1KMT2ATDP1 | |
| SCHEMBL21792805 | 0.74 | ADRB2 (0.64) | CASRTDP1TSHRADRB2ADRB1 | |
| SCHEMBL4367357 | 0.73 | KIF11 (0.44) | CASRMEN1KMT2A | |
| SCHEMBL2048837 | 0.71 | CTSK (0.36) | CASRMEN1KMT2ATSHR | |
| SCHEMBL4367349 | 0.70 | MEN1 (0.58) | CASRMEN1KMT2ATDP1 | |
| SCHEMBL14383158 | 0.67 | CASR (0.60) | CASRADRB2ADRB1ADRB3PTPN1 | |
| SCHEMBL12762284 | 0.67 | KCNN4 (0.48) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908829-B1 | OLIGONUCLEOTIDE PROBE | NAT INST OF ADVANCED IND SCIEN (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-7491857-B2 | Oligonucleotide probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080227968-A1 | Oligonucleotide Probe | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1908829-A1 | OLIGONUCLEOTIDE PROBE | National Institute of Advanced Industrial Science and Technology (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227968-A1 | Oligonucleotide Probe | APEX1, RNGTT, RNASEH1 | CASR 2347/4885MAPT 4572/4885MEN1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.